Monograph Details
|
|
Nutrition
> Obesity
|
|
XENICAL |
| Manufacturer |
|
Roche Laboratories |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Lipase inhibitor. |
| Generic Name |
|
Orlistat 120mg; caps. |
| Indications |
|
Adjunct to reduced-calorie diet in obesity management, including weight loss and weight maintenance. To reduce risk of weight regain after weight loss. For use in patients with initial body mass index ≥30kg/m2 or ≥27kg/m2 in the presence of other risk factors. |
| Children |
|
Not recommended. |
| Adults |
|
Use with a reduced calorie diet with about 30% of calories from fat; spread fat intake over 3 main meals. Take during or up to 1 hour after meals. 120mg three times daily with each of 3 main meals. If a meal is missed or has no fat, skip dose. |
| Contraindications |
|
Chronic malabsorption syndrome. Cholestasis. |
| Precautions |
|
Exclude organic causes of obesity. Hyperoxaluria. Calcium oxalate nephrolithiasis. Weight loss may affect doses needed for antidiabetic drugs (monitor). Pregnancy (Cat.B), nursing mothers: not recommended. |
| Interactions |
|
May decrease absorption of fat-soluble vitamins, beta carotene; supplement diet with a multivitamin (separate dosing by at least 2 hours). Monitor warfarin, cyclosporine. |
| Adverse Reactions |
|
GI effects (oily spotting, flatus with discharge, fecal urgency, fatty/oily stools, oily evacuation, increased defecation, fecal incontinence). |
| How Supplied |
|
Caps—90 |
|
|
|
|
